 The full data set was presented as part of the virtual Late-Breaker session of the American Academy of Dermatology. The significance of this Phase 2 Part B trial is that rilzabrutinib, a reversible covalent oral BTK inhibitor, demonstrated a 40 percent complete remission CR rate after 24 weeks of treatment while the median corticosteroid CS dose was reduced to 6 mg. It is also very encouraging to see that 60 and 87 percent of patients achieved control of disease activity CDA -- the primary endpoint -- by the 4th and 12th week, respectively, which is unusually fast, said Dr. Dedee Murrell, Professor and Head of the Department of Dermatology at The St. George Hospital Clinic School, University of New South Wales in Sydney, Australia, who is the Principal Investigator of the ongoing PEGASUS Phase 3 trial. 